Jamila Louahed - Vice President, Vaccine Research & Development, GSK Vaccines
Biography of the speaker:
Jamila Louahed leads the Belgium research and development organization of GSK vaccine, covering discovery, early and late development activities. She joined GSK in 2005, taking on roles of increasing responsibility in immunology, translational research and biomarkers for patient stratification. She was heading the research and development of cancer immunotherapeutic from discovery to late clinical development. After heading the cancer vaccine program, she was appointed in 2015 Head of R&D for infectious vaccines. She is in charge of the life cycle management of the commercial vaccines and the development of the elderly and therapeutic vaccine portfolio.
Before joining GSK, Jamila obtained her Ph.D. in Immunology and Molecular biology at Université Catholique de Louvain in Brussels and completed her post-doctoral training at Magainin Pharmaceuticals in Philadelphia. Her research has focused on the discovery and characterization of two cytokines (IL-9 & IL-22) as well as their role in cancer and chronic disorders. Following her post-doctoral training, Jamila held a senior researcher position at the Brussels branch of the Ludwig Institute for Cancer Research.